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Abstract
An estimated 50 million dengue virus (DENV) infections occur annually and more than forty percent of the human
population is currently at risk of developing dengue fever (DF) or dengue hemorrhagic fever (DHF). Despite the prevalence
and potential severity of DF and DHF, there are no approved vaccines or antiviral therapeutics available. An improved
understanding of DENV immune evasion is pivotal for the rational development of anti-DENV therapeutics. Antagonism of
type I interferon (IFN-I) signaling is a crucial mechanism of DENV immune evasion. DENV NS5 protein inhibits IFN-I signaling
by mediating proteasome-dependent STAT2 degradation. Only proteolytically-processed NS5 can efficiently mediate STAT2
degradation, though both unprocessed and processed NS5 bind STAT2. Here we identify UBR4, a 600-kDa member of the N-
recognin family, as an interacting partner of DENV NS5 that preferentially binds to processed NS5. Our results also
demonstrate that DENV NS5 bridges STAT2 and UBR4. Furthermore, we show that UBR4 promotes DENV-mediated STAT2
degradation, and most importantly, that UBR4 is necessary for efficient viral replication in IFN-I competent cells. Our data
underscore the importance of NS5-mediated STAT2 degradation in DENV replication and identify UBR4 as a host protein
that is specifically exploited by DENV to inhibit IFN-I signaling via STAT2 degradation.
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Introduction
Approximately fifty million dengue virus (DENV) infections
occur annually with more than forty percent of the human
population at risk of developing dengue fever (DF) or dengue
hemorrhagic fever (DHF). DF and its more severe form, DHF, are
potentially fatal diseases caused by the four serotypes (1, 2, 3 and 4)
of DENV [1]. As no approved vaccines or antiviral therapeutics
are available for the prevention or treatment of DENV infections,
it is imperative that the biology and immunology of DENV
infections are better understood. An in depth comprehension of
DENV-host interactions will accelerate our progress in developing
DENV therapeutics.
DENV, along with other clinically relevant arboviruses such as
West Nile virus (WNV), Japanese encephalitis virus (JEV) and
yellow fever virus (YFV), belongs to the flavivirus genus of the
Flaviviridae family. The flavivirus genome is a capped 11 kb
genome that is translated into a single polyprotein, which is
cleaved both by the viral protease (NS2B/3) and host proteases to
yield three structural proteins (capsid [C], membrane [prM/M]
and envelop [E]) and seven non-structural proteins (NS1, NS2A,
NS2B, NS3, NS4A, NS4B and NS5) [2,3]. The flavivirus
structural proteins incorporate the viral genome into newly
generated virions while the non-structural proteins replicate the
viral genome and exploit the cellular machinery to subvert host
immune responses. The approximately 900-amino-acid NS5
protein is the largest and most conserved flavivirus protein [4].
This multifunctional protein has RNA-dependent RNA polymer-
ase (RdRp) activity as well as methyltransferase activity [5,6,7,8,9].
In addition, more recent studies have shown that NS5 is a potent
interferon-signaling antagonist [10,11,12,13,14,15,16].
The significance of the interferon (IFN) response as an
important component of host immunity is underscored by
numerous examples of viruses that antagonize it
[17,18,19,20,21,22,23,24,25]. Viruses express pathogen-associated
molecular patterns (PAMPs) that trigger the production of type I
IFN (IFNa/b or IFN-I) [26]. Binding of IFN-I to the cell-surface
IFN-I receptor (IFNAR) initiates a signaling cascade that results in
the activation and phosphorylation of the Janus kinases, Jak1 and
Tyk2, and the transcription factors, STAT1 and STAT2.
Phosphorylated STAT1 and STAT2 along with IRF9 form the
heterotrimeric transcriptional complex, ISGF3 [27,28], and
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induce the expression of antiviral IFN-stimulated genes (ISGs)
[29,30,31,32].
DENV encodes several antagonists of both IFN-I production
and IFN-I signaling [13,14,33,34,35,36,37,38]. The NS5 proteins
of DENV and other flaviviruses have been shown to be potent
inhibitors of IFN signaling. NS5 proteins of different flaviviruses
may target different steps of the IFN signaling pathway. For
example, WNV NS5 prevents the phosphorylation of the STAT
proteins, while DENV NS5 binds human STAT2 and promotes its
proteasomal degradation [13,15].
Although STAT degradation is a common mechanism of viral
IFN antagonism [19,20,39,40], the requirements for DENV NS5-
mediated STAT2 degradation are unique. DENV NS5-mediated
STAT2 degradation requires NS5 to be proteolytically cleaved at
its N terminus from a larger precursor protein [13]. N-terminal
cleavage of NS5 normally occurs during DENV infection because
the NS2B/3 protease cleaves at the junction located between
NS4B and NS5 thereby releasing NS5 from the viral polyprotein
[41]. Though both unprocessed and proteolytically-processed NS5
can bind STAT2, only processed NS5 can efficiently mediate
STAT2 degradation [13]. Furthermore, the first ten amino acids
of NS5 are dispensable for STAT2 binding but are indispensable
for STAT2 degradation [13]. While the viral requirements for
DENV-mediated STAT2 degradation are known, the cellular
components were unspecified until now.
This study identifies the 600-kDa protein, UBR4, as a binding
partner of DENV NS5. UBR4 is a member of the N-recognin
family, which contains proven and predicted E3 ligases that
recognize and degrade proteins containing destabilizing N
termini [42]. UBR4 interacts preferentially with proteolytically-
processed DENV NS5 but not with YFV NS5 or WNV NS5,
highlighting the specificity of the DENV NS5/UBR4 interaction.
Furthermore, we have identified two residues within the first 10
N-terminal amino acids of NS5, threonine 2 and glycine 3, that
are required for NS5 binding to UBR4. These two residues are
conserved across the four DENV serotypes but are not found in
other flaviviruses. Finally, we show that UBR4 is required for
DENV-mediated STAT2 degradation, and for efficient DENV
replication in IFN-I competent cells. Our data confirm the
importance of NS5-mediated STAT2 degradation for DENV
replication, and identify UBR4 as a host protein that is
specifically co-opted by DENV to inhibit IFN-I signaling via
STAT2 degradation.
Results
DENV NS5 binds UBR4
DENV NS5 binds human and non-human primate STAT2 but
cannot efficiently mediate STAT2 degradation unless it is
expressed in the context of a precursor protein from which it is
N-terminally cleaved [13]. When DENV NS5 is engineered to be
expressed downstream of ubiquitin, cellular hydrolases cleave
ubiquitin in a manner that mimics the cleavage of NS4B away
from NS5 by the NS2B/3 protease during DENV infection [13].
To identify host proteins that are required for NS5-mediated
degradation of STAT2, we generated a DENV2 NS5 construct
consisting of RFP-ubiquitin fused to the NS5 N-terminus and a
TAP (tandem-affinity purification) tag fused to the NS5 C-
terminus. This NS5 construct was expressed in 293T cells, in the
presence or absence of human STAT2-FLAG, and then purified
using the TAP method. A high molecular weight protein band was
consistently and specifically co-precipitated with NS5 both in the
presence and absence of overexpressed STAT2 (Figure 1A).
Trypsin digestion of this band yielded five peptides that were
identified by mass spectrometry as sequences of the N-recognin,
UBR4 (Table 1) [42]. To confirm the binding and specificity of the
interaction between DENV2 NS5 and UBR4, HA-tagged DENV2
NS5, DENV1 NS5, and YFV NS5 were expressed in 293T cells
and purified by immunoprecipitation with antibodies raised
against the HA epitope. The NS5 protein of both DENV1 and
DENV2 precipitated UBR4 from 293T cells but YFV NS5 was
unable to precipitate UBR4 from these cells (Figure 1B). WNV
NS5 was also unable to bind UBR4 (Figure 1C). In order to assess
the specificity of DENV NS5 for UBR4, we also examined the
ability of NS5 to bind another member of the N-recognin family,
UBR5. DENV1 and DENV2 NS5 bound UBR4 but not UBR5,
further highlighting the unique interaction between UBR4 and
DENV NS5 (Figure 1B).
The UBR4-NS5 interaction correlates with NS5-mediated
STAT2 degradation
UBR4 was found to bind both processed (RFP-ubiquitin-NS5-
TAP) (Figure 1A), as well as unprocessed NS5 (NS5-HA)
(Figure 1B). Since cleavage of NS5 promotes STAT2 degradation,
we tested whether proteolytic processing would also affect the
binding efficiency of NS5 for UBR4. The E domain in Figure 2A
refers to the E protein of DENV2. Inclusion of a protein (such as E
or RFP) upstream of ubiquitin allows one to differentiate between
cleaved and uncleaved NS5 [13]. HA-tagged unprocessed NS5
(NS5-HA) and processed NS5 (proNS5-HA) (Figure 2A) were
expressed in 293T cells and the NS5 proteins were immunopre-
cipitated and tested for UBR4 binding. Although both constructs
precipitated UBR4, proNS5-HA precipitated two-fold higher
amounts of UBR4 than NS5-HA did (as quantified by densitom-
etry) (Figure 2B).
Given that the first 10 amino acids of NS5 are dispensable for
STAT2 binding but indispensable for STAT2 degradation [13],
we asked whether this N terminal region of NS5 was also
important for UBR4 binding. To test this, we expressed and
immunoprecipitated processed HA-tagged DENV NS5 proteins
containing a deletion of 10 or 306 residues at their N-termini, and
assessed their ability to bind UBR4. Full length HA-tagged NS5
(NS5-HA) was able to precipitate UBR4 and STAT2, and its
Author Summary
Dengue virus (DENV) is the leading cause of mosquito-
borne viral illness and death in humans. At present, there
are no vaccines and no specific antiviral therapeutics to
prevent or treat DENV infections. We previously described
that the NS5 protein of DENV inhibits type I interferon
signaling in virus-infected cells by mediating STAT2
degradation. This property allows DENV to overcome the
antiviral effects of type I interferon, contributing to viral
replication in the host. We have now obtained new insight
into the mechanism by which DENV NS5 induces STAT2
degradation. NS5 bridges STAT2 with the cellular protein
UBR4, a member of a family of predicted E3 ligases,
resulting in UBR4-mediated STAT2 degradation. Elimina-
tion of UBR4 or mutations in NS5 that prevent its binding
to UBR4 prevent NS5 from inducing STAT2 degradation.
Importantly, UBR4 is required for optimal DENV replication
in the presence of a competent type I interferon system.
Our data demonstrate the requirement of a host factor,
UBR4, for DENV to overcome the antiviral interferon
response. This information might be important for the
design of specific DENV inhibitors that prevent dengue
virus from evading innate immunity.
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ability to precipitate UBR4, but not STAT2, was increased
seven-fold (as quantified by densitometry) when DENV NS5 was
proteolytically-processed (proNS5-HA) (Figure 2C). Proteolyti-
cally-processed NS5 lacking the first 10 amino acids
(proD10NS5-HA) precipitated STAT2 but not UBR4, and
proteolytically-processed NS5 lacking the first 306 amino acids
(proD306NS5-HA) precipitated neither protein (Figure 2C).
When protein levels were examined in the whole cell extracts
(WCE), STAT2 was reduced in proNS5-HA-expressing cells
and slightly reduced in NS5-HA-expressing cells compared with
proD10NS5-HA- or proD306NS5-HA-expressing cells
(Figure 2C), which is consistent with published reports [13].
Thus, only the NS5 proteins that bound UBR4 could mediate
STAT2 degradation, and increased UBR4 binding by NS5
correlated with increased NS5-mediated STAT2 degradation.
The interaction of NS5 with UBR4 and the requirement for the
first 10 amino acids of NS5 in mediating this DENV NS5-UBR4
interaction was also observed by NS5-UBR4 colocalization
using immunofluorescence analysis in Vero cells (Figure 2D). To
further define which of the N-terminal residues of DENV NS5
are required for its interaction with UBR4, alanine scanning of
the first 5 amino acids of DENV NS5 was conducted (Figure 2E).
Immunoprecipitation experiments with these mutant proteins
revealed that the threonine (T) at position 2 and the glycine (G)
at position 3, which are conserved among the DENV serotypes
but absent in other flaviviruses, were required for NS5/UBR4
interaction and NS5-mediated STAT2 degradation (Figure 2F).
NS5 interaction with UBR4 is independent of STAT2
The fact that NS5 mutants lacking residues T2 or G3 bound
STAT2 but not UBR4 (Figure 2F) suggested that the
interaction between NS5 and UBR4 was independent of
STAT2. To confirm this result, the STAT2-deficient U6A cell
line [43] was transfected with proNS5-HA or proD10NS5-HA.
ProNS5-HA, but not proD10NS5-HA, precipitated UBR4 from
U6A cells (Figure 3A). Unlike with human STAT2 (hSTAT2),
NS5 does not bind and subsequently degrade mouse STAT2
(mSTAT2) [44]. The STAT2 proteins of mouse and human are
divergent and share only 70% identity but the UBR4 proteins
of mouse and human are 97% identical. When proNS5-HA was
expressed in mouse cells (Hepa1.6), mouse UBR4 bound
proNS5-HA but not proD10NS5-HA confirming that an
interaction between NS5 and STAT2 is not required for NS5
to interact with UBR4 (Figure 3A). These data suggest that NS5
requires binding to both UBR4 and STAT2 to mediate STAT2
degradation.
Human STAT2 forms a complex with UBR4 in the
presence of DENV NS5
NS5 binds the coiled-coil region located within the first half of
hSTAT2 [44]. Though mSTAT2 and human STAT1 (hSTAT1)
cannot bind NS5, chimeric proteins that replace the first 301
amino acids of mSTAT2 (h/mSTAT2) or the first 316 amino
acids of hSTAT1 (hSTAT2/1) with those of hSTAT2 can bind
NS5 [44]. We expressed and immunoprecipitated FLAG-tagged
STAT proteins and STAT chimeric proteins in the presence or
absence of proNS5-HA. When hSTAT2 was overexpressed,
STAT2 degradation was not observed because STAT2 degrada-
tion was likely masked by the large amount of overexpressed
STAT2 present (Figure 3B). However, we observed that while
hSTAT1 and mSTAT2 did not bind UBR4, h/mSTAT2,
hSTAT2/1 and hSTAT2 all bound UBR4 in the presence of
proNS5-HA (Figure 3B). Since only those STAT molecules that
could bind NS5 could also bind UBR4, and NS5 binds UBR4 in
the absence of STAT2, we conclude that NS5 serves as a bridge
molecule between STAT2 and UBR4.
These results were confirmed in the context of DENV infection
of a transformed human cell line (293T) and primary untrans-
formed human cells (monocyte-derived dendritic cells or MDDCs)
(Figure 3C and 3D). Cells were infected with DENV2 at an MOI
of 3 for 24 hours, and lysed for immunoprecipitation with STAT2
Figure 1. DENV NS5 binds UBR4. (A) RFP-ubiquitin-NS5-TAP was
expressed in 293T cells, in the presence or absence of human STAT2-
FLAG, and then purified using the tandem affinity purification (TAP)
method. The purified proteins were resolved on an SDS 4–15% gel that
was then stained with silver. *NS5 and STAT2 run in similar positions in
the gel. The bands highlighted by the arrows were analyzed by mass
spectrometry at Taplin Biological Mass Spectrometry Facility, Harvard
Medical School. (B and C) HA-tagged DENV2, DENV1, WNV and/or YFV
NS5 proteins were immunoprecipitated from 293T cells using anti-HA
beads. Immunoblot (IB) analysis of the immunoprecipitate (IP) and
whole cell extract (WCE) was performed against UBR4, UBR5, STAT2, HA
and/or b-tubulin.
doi:10.1371/journal.ppat.1003265.g001
Table 1. UBR4 peptides identified by mass spectrometry.
Peptide sequence
Position in UBR4 protein (NCBI Accession #
Q5T4S7)
RISESLVRH 1750–1758
KSFAATISRT 2130–2139
RIQIGTQAIERA 2353–2364
RALATNPALRH 3888–3898
RQVLFTPATQAARQ 4130–4143
doi:10.1371/journal.ppat.1003265.t001
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antibodies or control IgG. Although the majority of STAT2 was
degraded during DENV infection, the remaining STAT2 co-
immunoprecipitated UBR4 from DENV-infected cells but not
from mock-infected cells (Figure 3C and 3D), which is consistent
with NS5 binding to and bringing together STAT2 and UBR4
during DENV infection.
UBR4 promotes DENV-mediated STAT2 degradation
We next assessed the functional relevance of UBR4 in DENV-
mediated STAT2 degradation. To test if UBR4 is required for
DENV-mediated STAT2 degradation, UBR4 levels were stably
reduced in 293T cells using small hairpin RNA (shRNA) directed
against UBR4. Three stable UBR4-knockdown cell lines were
Figure 2. The UBR4-NS5 interaction correlates with NS5-mediated STAT2 degradation. (A) A representation of the DENV2 NS5 constructs
used in this study. The E domain upstream of ubiquitin refers to the E protein of DENV2. (B and C) HA-tagged DENV NS5 constructs were
immunoprecipitated from 293T cells using anti-HA beads. Immunoblot (IB) analysis of the immunoprecipitate (IP) and whole cell extract (WCE) was
performed against UBR4, STAT2, HA and b-tubulin or GAPDH. (D) Vero cells expressing HA-tagged DENV NS5 constructs were fixed for
immunofluorescence (IF) analysis of UBR4 (green) and NS5 (red). The nuclei were also stained with DAPI (blue). (E) An alignment of the first 10 or 11
amino acids of NS5 from several flaviviruses. Residues that are conserved in all examined flaviviruses are highlighted in green, while those residues
that are only conserved amongst the four DENV serotypes are highlighted in red. (F) GFP-tagged DENV2 NS5 constructs and DENV2 NS5 point
mutants were immunoprecipitated from 293T cells using anti-GFP antibody and protein G beads. Immunoblot (IB) analysis of the immunoprecipitate
(IP) and whole cell extract (WCE) was performed against UBR4, STAT2, GFP and b-tubulin.
doi:10.1371/journal.ppat.1003265.g002
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Figure 3. NS5 promotes STAT2 association with UBR4. (A) Proteolytically-processed HA-tagged DENV2 NS5 constructs or an empty vector
were expressed in human cells that naturally express human STAT2 (293T cells), human cells that do not express STAT2 (U6A cells), or murine cells
that naturally express mouse STAT2 (Hepa1.6), and the lysates of these cells were subjected to anti-HA immunoprecipitation. Immunoblot (IB)
analysis of the immunoprecipitate (IP) and whole cell extract (WCE) was performed against UBR4, human STAT2, mouse STAT2, HA and b-tubulin. (B)
FLAG-tagged STAT constructs were overexpressed in 293T cells with or without proteolytically-processed HA-tagged DENV2 NS5.
Immunoprecipitation was performed against the FLAG epitope, then IB analysis of the IP and WCE was performed against UBR4, FLAG, HA and
GAPDH. hSTAT2= human STAT2; mSTAT2=mouse STAT2; hSTAT1=human STAT1; h/mSTAT2= a chimeric protein with the first 301 amino acids of
mouse STAT2 replaced by the corresponding human STAT2 sequence; hSTAT2/1= a chimeric protein with the first 316 of human STAT1 amino acids
replaced by the corresponding human STAT2 sequence. (C) 293T cells and (D) monocyte-derived dendritic cells (MDDC) were mock infected or
infected with DENV2 (Thailand/16681 strain) at an MOI of 3 for 24 hours then lysed for IP with anti-STAT2 antibody or control IgG. IB analysis of the IP
and WCE was performed against UBR4, UBR5, STAT2, DENV NS5 and b-tubulin.
doi:10.1371/journal.ppat.1003265.g003
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generated using shRNA that targeted different sequences within
UBR4. The cells were mock infected or infected with DENV2 at
an MOI of 10, and lysed for western blot analysis at 4, 8, 12 and
24 hours post-infection. When cells expressing control non-
targeting shRNA were infected with DENV2, STAT2 levels
decreased by 4 hours post-infection. However, in the three
independently-derived, UBR4-deficient 293T cell lines, STAT2
levels decreased at a slower rate (Figure 4A). Furthermore, NS5
levels were lower in the UBR4-knockdown cells than in the control
cells suggesting that there was a DENV replication defect in
UBR4-knockdown cells. The similar phenotype of the three
UBR4-knockdown cell lines and their difference from the control
cell line indicated that the effect of UBR4 knockdown on DENV-
mediated STAT2 degradation was due to the decreased level of
UBR4 and not to off-target effects of the shRNA. We next
examined the functional relevance of UBR4 in mediating STAT2
degradation with the other three DENV serotypes (DENV1, 3 or
4). STAT2 levels were higher and NS5 levels were lower in
shUBR4-expressing cells than in control cells (Figure 4B). Thus,
UBR4 is required for efficient STAT2 degradation mediated by all
four DENV serotypes.
The UBR4 gene is predicted to produce several splice variants
encoding proteins of greater than 5000 amino acids. Since it is
unclear which UBR4 isoform is required for DENV-mediated
STAT2 degradation, we cloned a region of UBR4 (UBR4-NT)
that is predicted to be present in all the large UBR4 isoforms and
which also contains the UBR box, a 70-amino-acid zinc-finger-like
domain required for recognition of N-end rule substrates [42]. The
UBR box is located between amino acids 1662–1723 of the UBR4
reference sequence (NCBI Accession # Q5T4S7), and the UBR4-
NT clone encodes amino acids 1–2233 of the reference sequence.
Co-immunoprecipitation experiments revealed that proNS5-HA
did not bind amino acids 1–2233 of UBR4 (Figure 4C) indicating
that sequences in the C-terminal half of UBR4 are required to
mediate its interaction with NS5. Also, expression of UBR4-NT
had no effect on DENV-mediated STAT2 degradation
(Figure 4D). The experiments in Figure 4 confirm that a functional
UBR4-NS5-STAT2 complex is required for efficient STAT2
Figure 4. UBR4 promotes DENV-mediated STAT2 degradation. (A) 293T cells stably expressing non-targeting shRNA (shControl) or shRNA
against UBR4 (shUBR4) were infected with DENV2 (Thailand/16681 strain) at an MOI of 10. Each shUBR4 clone expressed shRNA targeting different
sequences within the UBR4 gene. Lysates from mock-infected cells (M) and cells that been infected with DENV2 for 4, 8, 12 or 24 hours were
subjected to immunoblot (IB) analysis against UBR4, UBR5, STAT2, DENV NS5 and b-tubulin. (B) Lysates from shControl and shUBR4 293T cells that
had been mock infected or infected with DENV1, DENV3 or DENV4 at an MOI of 1 for 24 hours were subjected to IB analysis. (C) A proteolytically-
processed HA-tagged DENV NS5 construct or empty vector were transfected into 293T cells stably expressing a V5-tagged construct of the first 2233
amino acids of UBR4 (UBR4-NT). The lysates of these cells were subjected to anti-HA immunoprecipitation. Immunoblot (IB) analysis of the
immunoprecipitate (IP) and whole cell extract (WCE) was performed against UBR4, human STAT2, V5, HA and b-tubulin. (D) 293T cells expressing
UBR4-NT were mock infected or infected with DENV at an MOI of 1. Lysates were subjected to IB analysis against STAT2, V5, NS5 and b-tubulin at
24 hours post infection.
doi:10.1371/journal.ppat.1003265.g004
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degradation and that multiple domains of UBR4 are required for
this function.
UBR4 enhances the replication of DENV in an IFN-I-
dependent manner
The ability of DENV to degrade STAT2 determines how well
it replicates in an IFN-I-competent cell [44]. Thus, a protein
that is required for DENV-mediated STAT2 degradation
should also enhance DENV replication in IFN-I-competent
cells. To test if UBR4 is required for DENV replication, UBR4-
knockdown 293T cells were infected with DENV2 at multiplic-
ities of infection (MOI) of 0.1, 1 and 10, and measured for virus
at 24 hours post-infection. DENV replicated to lower levels in
UBR4-knockdown cells than in control cells (Figure 5A). The
replication defect was most striking at a lower MOI and an
approximately 10-fold decrease in virus levels was observed in
shUBR4 cells with an MOI of 0.1 of DENV. In contrast, UBR4
depletion had no effect on the replication of YFV or
encephalomyocarditis virus (EMCV), a positive-strand RNA
virus belonging to the Picornaviridae family, indicating a specific
requirement of UBR4 in DENV replication (Figure 5A).
DENV1, 3 and 4 also replicated to lower levels in UBR4-
knockdown cells than in control cells indicating that UBR4 is
required for the efficient replication of all four DENV serotypes
(Figure 5B).
Figure 5. UBR4 enhances the replication of DENV in an IFN-I-dependent manner. (A) 293T cells stably expressing non-targeting shRNA
(shControl) or shRNA against UBR4 (shUBR4 #2) were infected with DENV2 (Thailand/16681 strain), YFV (17D strain) or EMCV at the indicated
multiplicities of infections (MOI). Cells and media were harvested at 24 hours post-infection and measured for virus by plaque assay on BHK-21 cells.
(B) 293T cells were infected with DENV1, 2, 3 or 4 at an MOI of 1 and the virus levels were measured by plaque assay on BHK-21 cells 24 hours later.
(C) Vero cells stably expressing non-targeting shRNA (shControl) or shRNA against UBR4 (shUBR4 #1) were infected with DENV2 (Thailand/16681
strain) at an MOI of 0.1. Cells were mock-treated or treated with IFN-I (1000units/ml IFNb) at 6 hours post infection. Cells and media were harvested at
24 hours post-infection for plaque assay or immunoblotting (IB) with antibodies against UBR4, STAT2, NS5 and b-tubulin. (C) 293T cells were infected
with DENV2 at an MOI of 1 and incubated with media containing 0.1 mg/ml control IgG antibody or 0.1 mg/ml IFNAR antibody. Cells and media were
harvested at 24 hours post-infection and measured for virus by plaque assay on BHK-21 cells. (D) 293T clones were infected with DENV2 at an MOI = 1
and their RNA harvested at the indicated time post infection. The levels of ISG54 mRNA were measured by qPCR, normalized to 18s (a housekeeping
gene) and represented as fold induction over mock samples.). Each graph represents the mean +/2 the standard deviation of 6 experiments (A), 3
experiments (B, C and D), or 2 experiments (E). Statistical analyses were conducted using the unpaired t test function of Prism 4 for Macintosh
(GraphPad Software, USA). *p,0.05; **p,0.01; *** p,0.001; ns = not statistically significant, where p.0.05.
doi:10.1371/journal.ppat.1003265.g005
Dengue Virus Co-opts UBR4 to Degrade STAT2
PLOS Pathogens | www.plospathogens.org 7 March 2013 | Volume 9 | Issue 3 | e1003265
Since UBR4 was required for DENV-mediated STAT2
degradation, we hypothesized that the DENV replication defect
in UBR4-deficient cells was due to an inability of DENV to
antagonize IFN-I signaling by degrading STAT2. If this is the
case, lack of IFN-I should compensate for the requirement of
UBR4 in DENV replication. To test this, we infected control and
UBR4-knockdown Vero cells with DENV. Vero cells lack IFN-I
genes and therefore cannot make IFN-I in response to viral
infection [45]. DENV replicated to similar levels in UBR4-
knockdown and control Vero cells (Figure 5C). Yet when Vero
cells were infected with DENV and then exogenously treated with
IFN-I 6 hours later, a DENV replication defect was observed in
the UBR4-deficient Vero cells (Figure 5C). Protein levels of NS5,
UBR4, and STAT2 in UBR4-knockdown Vero cells showed that
UBR4 levels were indeed lower and that DENV-mediated STAT2
degradation was defective in UBR4-knockdown cells (Figure 5B).
Treating DENV-infected UBR4-knockdown 293T cells with a
neutralizing anti-IFNAR antibody corroborated the effect of IFN-I
on DENV replication in UBR4-deficient Vero cells (Figure 5D).
We observed a significant increase in DENV replication in UBR4-
knockdown 293T cells treated with the neutralizing anti-IFNAR
antibody compared to UBR4-knockdown 293T cells treated with
IgG control antibodies. This contrasts with what was observed in
control 293T cells where DENV replication was unaffected by
treatment with anti-IFNAR antibodies (Figure 5D).
IFN exerts its biological effect by upregulating interferon-
stimulated genes (ISGs), which encode products that restrict viral
replication. To examine the biological relevance of UBR4 in
preventing the antiviral action of IFN-I during DENV infection,
we examined the induction of ISG54 mRNA in UBR4-
knockdown 293T cells. There was a significant induction of
ISG54 mRNA in UBR4-knockdown cells during DENV infection
compared to control cells (Figure 5E). These results indicate that
UBR4 is required for preventing the antiviral action of IFN-I
during DENV infection.
Dendritic cells are thought to be an important cell type in which
DENV replicates in vivo [46,47]. We reduced UBR4 levels in
primary MDDCs from five donors using shRNA lentiviral
constructs, and tested the effect of this decrease on DENV
replication. When MDDCs from each donor were infected at an
MOI of 3, approximately 35% of transfected cells were highly
infected and showed viral glycoprotein (E) expression by FACS. At
12 hours post infection, as expected, the levels of UBR4 were
decreased in the UBR4-knockdown cells compared to control cells
(Figure 6A). When the levels of ISG15, RIG-I and ISG54 mRNA
were analyzed in these cells, more ISGs were induced in four of
the five donors (Figure 6B, 6C and 6D respectively). In addition,
more DENV was present in control cells than in UBR4-
knockdown cells at 48 hours post infection (Figure 6E). Thus,
UBR4 is required for inhibiting ISG induction and increasing
DENV replication in a primary cell type that is of importance in
DENV infections.
Discussion
The IFN-I response is one of the first lines of protection against
DENV infection, and serves to curb viral replication and
dissemination by generating an antiviral intracellular environment
[48]. The potency of the type I IFN pathway is exemplified by the
fact that DENV antagonizes both IFN synthesis and IFN signaling
in order to ensure its replication and survival
[13,14,33,34,35,36,37,38]. DENV NS5 inhibits IFN-I signaling
by mediating proteasome-dependent STAT2 degradation, and
STAT2 degradation promotes DENV replication [13,14,44].
With this study, we report the discovery of a host factor, UBR4,
that is essential for DENV-dependent STAT2 degradation. We
describe the interaction of UBR4 with NS5 and show that this
interaction is crucial for inhibiting type-I IFN signaling and
promoting efficient DENV replication.
UBR4 associates with DENV NS5 but not with the closely
related YFV NS5 or WNV NS5. UBR4 also binds preferentially to
proteolytically-processed DENV NS5, which is the form of NS5
that efficiently mediates STAT2 degradation. Binding of UBR4 to
DENV NS5 requires amino acids T2 and G3 of NS5, which are
also critical for STAT2 degradation. These amino acids are
conserved amongst the four DENV serotypes but are absent in
other flaviviruses (Figure 2F). Though NS5 is the most highly
conserved flavivirus protein, the high degree of specificity
exhibited by UBR4 for DENV NS5 underscores the differences
between the various flaviviral NS5 proteins.
In 293T cells and primary human dendritic cells, DENV
replicates best when UBR4 levels are normal, but when UBR4
levels are reduced, DENV-mediated STAT2 degradation is
reduced and DENV replication decreases as a consequence
(Figures 5 and 6). In Vero cells, which do not produce IFN-I [45],
UBR4 depletion does not affect DENV replication unless these
cells are treated with exogenous IFN-I (Figure 5C). Furthermore,
the DENV replication defect caused by UBR4 knockdown in
293T cells can be decreased by treating the cells with antibodies
that block the IFN-I receptor and decrease IFN-I signaling
(Figure 5D). The DENV replication defect seen in UBR4-
knockdown 293Ts and MDDCs can be explained by an increase
in ISG levels in DENV-infected UBR4-knockdown cells versus
DENV-infected control cells (Figure 5E and Figure 6). Thus, in the
absence of IFN-I, there is no need for DENV to antagonize IFN-I
signaling and cellular levels of UBR4 are irrelevant for DENV
replication. However, upon activation of the IFN-I signaling
pathway, UBR4 becomes necessary for DENV replication.
Reducing STAT2 levels is essential for DENV to preempt the
establishment of a cellular antiviral state, thus ensuring its efficient
replication.
Antagonism of IFN signaling is one of the factors responsible for
the limited host tropism of DENV to human and nonhuman
primates. DENV does not replicate to high levels or induce disease
in IFN-competent mice [44,49]. Our previous results indicated
that the cellular machinery needed for DENV replication in
murine cells is in place but is limited by the inability of NS5 to
associate with murine STAT2 and inhibit murine IFN-I signaling
[44]. Other blocks such as the type II IFN pathway also diminish
DENV replication in mice, but the IFN-I signaling pathway
restricts early replication [44,50]. Here we show that DENV NS5
associates with murine UBR4 in murine cells. This is in keeping
with our previous results [44], and suggests that the development
of a genetically-modified mouse that expresses a functional human
STAT2 in place of its murine counterpart should allow increased
DENV replication. We predict, therefore, that DENV NS5 will
mediate human STAT2 degradation in these mice by co-opting
mouse UBR4. Such a mouse might provide the basis for the
development of an immune-competent mouse model of DENV
infections.
The 600 kDa large UBR4 is highly conserved and found in
organisms as diverse as mammals, insects, plants and worms. It
belongs to the N-recognin family, which contains proven and
predicted E3 ligases that recognize and degrade proteins
containing destabilizing N termini. The seven members of the
UBR family, UBR1 to UBR7, encode a 70-amino-acid zinc finger
motif known as the UBR box, which is necessary for substrate
recognition [42]. The better-characterized members of the UBR
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family are UBR1, UBR2 and UBR5. UBR1 and UBR2 are RING
domain-containing N-recognins, which recognize N-end rule
substrates and target them for degradation [42]. UBR1 and
UBR2 are also involved in N-end-rule-independent quality control
protein degradation [51]. UBR5 is a HECT-domain containing
E3 ligase that binds N-end rule substrates [42], but can also target
non-N-end rule substrates like E6AP for degradation [52]. UBR4
contains neither a HECT nor a RING domain.
A dearth of UBR4 literature exists because of the difficulty that
manipulating the UBR4 gene presents. The UBR4 gene contains
106 exons, and produces multiple splice variants that conceivably
have different functions. UBR4 forms a chromatin scaffold when
bound to retinoblastoma protein (Rb) in the nucleus, and it also
influences cytoskeleton organization by binding clathrin in the
cytoplasm [53]. Both of these are structural roles for which no N-
end rule or other E3 ligase activities have been detected. A second
virus, human papilloma virus, is known to exploit UBR4’s role in
cellular morphology to initiate anchorage-independent growth and
cellular transformation [54,55]. Although UBR4 is part of a family
of UBR E3 ligases involved in the N-end rule pathway, the
involvement of the N-end rule in the NS5-dependent degradation
of STAT2 seems unlikely. Our group has previously demonstrated
that the identity of NS5’s first residue is not relevant for STAT2
degradation as long as the precursor is correctly processed [13]. In
addition, we show that residues T2 and G3 of NS5 are critical for
binding to UBR4 and for mediating STAT2 degradation, but they
are considered to be stabilizing residues within the N-end rule.
This does not exclude UBR4 from having E3 ligase activity that is
independent of the N-end rule. Though it lacks an obvious
catalytic domain such as the HECT or RING domains, UBR4
contains a cysteine-rich domain (CRD) that is unique to the UBR4
group. It is currently unknown if CRD functions as a ligase
domain. Our experiments with the N-terminal region of UBR4
suggest that domains from the C terminus, which contain the
Figure 6. UBR4 enhances the replication of DENV in monocyte-derived dendritic cells. Monocytes from 5 donors were transduced with a
non-targeting shRNA lentivirus (shControl) or an shRNA lentivirus against UBR4 (shUBR4 #2). Monocytes were differentiated for 5 days to monocyte-
derived dendritic cells (MDDCs) before infecting with DENV2 (Thailand/16681 strain) at an MOI of 3. Cells were harvested at 12 hours post infection
for measurement of (A) UBR4, (B) ISG15, (C) RIG-I, and (D) ISG54 mRNA levels, or (E) supernatants were harvested at 48 hours post infection for
measurement of virus levels via plaque assay. RIG-I mRNA was undetectable in 1 donor. Statistical analyses were conducted using the two-way
ANOVA function of Prism 4 for Macintosh (GraphPad Software, USA). p,0.001 for UBR4, ISG15, RIG-I and ISG54 levels and p,0.01 for DENV titers in
shControl versus shUBR4 cells.
doi:10.1371/journal.ppat.1003265.g006
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CRD, are necessary for its function in DENV-mediated STAT2
degradation.
Finally, we propose two working models: one based on the
hypothesized UBR4 E3 ligase catalytic activity, and another which
postulates a scaffolding role for UBR4 based on its described
interactions with clathrin and retinoblastoma protein (Figure 7).
Efforts are currently being made to clone and express the
predicted UBR4 isoforms so as to further evaluate the function
of UBR4 in DENV-mediated STAT2 degradation, and to explore
its potential as a target for rationally-designed DENV therapeutics.
Materials and Methods
Cell lines and viruses
293T, Hepa1.6, U6A, BHK and Vero cells were maintained in
DMEM (Life Technologies) supplemented with 10% fetal bovine
serum (Life Technologies) and 1% penicillin/streptomycin mix
(Life Technologies). C6/36 cells were maintained in RPMI 1640
medium supplemented with 10% fetal bovine serum (Life
Technologies). Hepa1.6 cells were kindly provided by Matthew
Evans (Mount Sinai School of Medicine, New York, NY). U6A
cells were a kind gift of George Stark (Lerner Research Institute,
Cleveland, OH) and were previously described [43].
High-titer stocks of DENV1, DENV2, DENV3, DENV4,
yellow fever virus (YFV-17D) and encephalomyocarditis virus
(EMCV) were obtained by passage in C6/36 cells, BHK cells, and
Vero cells, respectively.
Plasmids and transfections
pCAGGS-CTAP was a kind gift from Luis Martinez-Sobrido
(University of Rochester). A gene cloned into pCAGGS-CTAP
produces a fusion protein that is C-terminally tagged with a TAP
tag: calmodulin binding protein followed by two tobacco etch virus
(TEV) cleavage sites followed by a protein A tag. The sequences of
the primers used for the construction of the RFP-ubiquitin-NS5
fragment that was cloned into pCAGGS-CTAP are available upon
request. The primers sequences used for cloning UBR4-NT (1–
2233 of UBR4, NCBI Accession Q5T4S7) into pCDNA6 are also
available upon request. All other viral gene expression constructs
were cloned into pCAGGS-HA and were described previously
[13,15]. The Flag-tagged STAT1, STAT2 and chimeric STAT
constructs were previously described [44].
All cells were transfected using Lipofectamine 2000 (Invitrogen)
according to the manufacturer’s protocol. 293T cells were
transfected at a ratio 1:2 (mg plasmid DNA: mL Lipofectamine
2000) while Vero, Hepa1.6 and U6A cells were transfected at a
ratio 1:3.
Tandem affinity purification and immunoprecipitation
Cells were lysed for tandem affinity purification (TAP) or
immunoprecipitation two days post transfection. For tandem
affinity purification, cells were lysed in TAP buffer (25% glycerol,
50 mM Tris HCL pH 8, 0.5% NP40, 200 mM NaCl, 1 mM b-
mercaptoethanol, protease inhibitor cocktail (Roche). Lysates were
spun at 15,000 g for 10 minutes and the supernatant was
Figure 7. Model of DENV-mediated STAT2 degradation. NS2B/3 protease cleaves NS4B away from NS5 to yield proteolytically-processed NS5.
Proteolytically-processed NS5 brings STAT2 into contact with the degradation machinery of the cell by binding UBR4. UBR4 may function as an E3
ligase (A), but as it lacks a known E3 ligase catalytic domain such as the HECT or RING, it may instead act as the recognition component or scaffold of
an E3 ligase complex (B). STAT2 degradation prevents the establishment of an antiviral state thereby allowing DENV to replicate optimally.
doi:10.1371/journal.ppat.1003265.g007
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incubated with IgG beads (Roche) for 4 hours then washed with
TAP buffer. The beads were then incubated with TEV buffer
(TAP buffer containing 0.5 mM EDTA, 1 mMDTT units) and 50
units AcTEV enzyme (Invitrogen) overnight. The beads were spun
at 15,000 g for 10 minutes then the supernatant was applied to
calmodulin beads (Roche) in a calmodulin bead (CB) buffer (TAP
buffer containing 4 mM CaCl2 and 2 mM imidazole) for 8 hours,
then washed in CB buffer. The protein was eluted from the
calmodulin beads by boiling for five minutes in Laemmli sample
buffer (BioRad).
For immunoprecipitation, cells were lysed in TAP buffer then
incubated for two hours with anti-FLAG or anti-HA beads
(#F2426 and #E6779 respectively, Sigma-Aldrich) or for 4 hours
with rabbit anti-STAT2 antibody (Santa Cruz) or mouse anti-GFP
antibody (Abcam) followed by 2 hours of protein A-agarose
(Roche) or protein G-agarose (Roche), respectively. The beads
were washed with TAP buffer then the protein was eluted from the
beads by boiling for five minutes in Laemmli sample buffer
(BioRad).
Western blot analysis of transfected and infected cells
Proteins lysates were boiled with Laemmli sample buffer and
resolved on 4–15% or 7.5% gels (BioRad) and then transferred to
PVDF membrane (Millipore) by standard methods. Membranes
were blocked with 3% BSA in TBS-Tween (20 mM Tris-HCl,
pH 7.4; 150 mM NaCl; 1% Tween) and then incubated with
antibodies and subjected to western blot. Benchmark Protein
Ladder (Invitrogen) was used to depict the size of protein bands.
The primary antibodies used in this study were: rabbit anti-human
STAT2 (sc-476, Santa Cruz), rabbit anti-mouse STAT2 (4597,
Cell Signaling), rabbit anti-STAT1 (610120, BD Biosciences),
mouse anti-b-tubulin (T0198, Sigma-Aldrich), mouse anti-HA
(H9658, Sigma-Aldrich), mouse anti-Flag (F3165, Sigma-Aldrich),
mouse anti-V5 (R960-25, Invitrogen), rabbit anti-UBR4 (ab86738,
Abcam), HRP-linked anti-GAPDH (ab9385, Abcam), rabbit anti-
UBR5 (ab70311, Abcam), and rabbit anti-NS5 [13]. The
secondary antibodies used in this study were HRP-linked anti-
mouse IgG (#NA931V, GE Healthcare) and HRP-linked anti-
rabbit IgG (#NA934V, GE Healthcare). Where indicated,
quantification of western blots was done by using Image J to
compare the ratio of UBR4 (seen as two bands or one band based
on the resolution of the tris-glycine gel used) to NS5.
Immunofluorescence
To analyze the intracellular localization of endogenous UBR4
and DENV NS5, Vero cells that had been grown on glass cover
slips were transfected with 1 mg of the indicated plasmids. After
24 hours post infection, cells were fixed and permeabilized for
30 minutes with ice cold methanol acetone (1:1, v/v) and 0.5%
NP-40, then washed with PBS. Following PBS washes, cells were
blocked in blocking buffer (0.2% cold waterfish gelatin (Sigma-
Aldrich, USA) and 0.5% BSA in PBS) for 1 hour at room
temperature (RT), and stained with primary antibodies (anti-
UBR4 at a 1:100 dilution, and anti-HA at a 1:1000 dilution)
overnight at 4uC. The cells were washed in PBS and incubated
with secondary antibodies to Alexa Fluor 488 and Alexa Fluor 555
(Invitrogen, USA) at 1:500 dilution in blocking buffer for 1 hour at
RT. Nuclear chromatin staining was performed by incubation in
blocking solution containing 0.5 mg/ml 49,6-diamidino-2-pheny-
lindole, DAPI (Sigma-Aldrich). Cells were washed and coverslips
mounted using Prolong antifade reagent (Invitrogen). Images were
captured using a Leica SP5-DM confocal microscope at the
Microscopy Shared Research Facility at Mount Sinai School of
Medicine.
Establishment of knockdown cell lines with lentiviruses
expressing shRNA
The 293T and Vero cell lines stably expressing non-silencing
shRNA or shRNA against UBR4 were made by infecting cells
with shRNA-encoding lentiviruses (according to the manufactur-
er’s protocol) and selecting cells with puromycin (1 mg/ml for
293T cells and 5 mg/ml for Vero cells) for two weeks before
DENV, YFV or EMCV infection.
The lentiviruses used to make 293T shUBR4 clones were
purchased from Open Biosystems. Lentivirus 1 (Clone ID:
V3LHS_318553; target sequence: CGCTTCGACTT-
CATGCTCT) targets nucleotides 11132–11150 of UBR4. Len-
tivirus 2 (Catalog #: V3LHS_318554; target sequence: CGGAT-
CAGCTCCTATGTCA) targets nucleotides 3140–3158 of UBR4.
Lentivirus 3 (Catalog #: V3LHS_318555; target sequence:
AGGTTTTTGTCTACAATGA) targets nucleotides 2357–2375
of UBR4. The non-silencing control lentivirus was catalog number
RHS4348. The Vero shUBR4 clone was made using lentivirus 1,
while the Vero shControl was made using non-silencing control
lentivirus.
Infection of 293T and Vero cells
Cells were infected at the indicated multiplicity of infection
(MOI) and maintained in DMEM with 10% FBS. For exogenous
IFN-I treatment of Vero cells, 1000 units/ml IFNb (PBL
Interferon Source) were added at 6 hours post infection. For
western blotting, cells were lysed with TAP buffer at each time
point and the lysates were clarified by centrifugation then boiled in
Laemmli sample buffer. For virus titration, cells and media were
frozen at each time point and clarified by centrifugation. DENV
and YFV titers were measured by plaque assay on BHK-21 cells,
and EMCV titers were measured by plaque assay on Vero cells.
Isolation, transduction and stimulation of MDDCs
Peripheral blood mononuclear cells were isolated from buffy
coats of healthy human donors by Ficoll density gradient
centrifugation (Histopaque, Sigma Aldrich) as previously described
[33]. Buffy coats were obtained from the Mount Sinai Blood
Donor Center and New York Blood Center. Briefly, CD14+ cells
were purified using anti-human CD14 antibody-labeled magnetic
beads and iron-based MiniMACS LS columns (Miltenyi Biotech).
After elution from the columns, 26105 cells were plated in 96-well
plates and transduced with VSV-G pseudo-typed SIV VLPs
(pSIV3+, an SIV gag-pol expression plasmid containing Vpx) and
lentiviral control or UBR4-specific shRNA vectors for 3 hours by
spinoculation in the presence of 2 mg/mL polybrene (Sigma) with
sufficient viruses to transduce .95% of the cells. Subsequently,
cells were washed, resuspended in DC medium (RPMI medium
[Invitrogen], 10% fetal calf serum [HyClone], 100 U/ml penicil-
lin, and 100 mg/ml streptomycin [Invitrogen]) supplemented with
500 U/ml human granulocyte-macrophage colony-stimulating
(Peprotech), and 1,000 U/ml human interleukin-4 (hIL-4; Pepro-
tech), and incubated for 5 days at 37uC. At 5 days post
transduction, MDDCs were either mock infected or infected with
DENV2 at an MOI of 3. At 12 hours post infection (hpi) cells were
harvested for qPCR analysis, and at 48 hpi supernatants were
collected for titration of virus levels by plaque assay on BHK-21
cells. Cells were also harvested for cytometry analysis.
Quantitative RT-PCR (qPCR)
Total RNA was isolated from samples using the RNeasy kit
(Qiagen) and subjected to DNase digestion with Turbo DNase
(Ambion). Reverse transcription was performed using the high
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capacity cDNA reverse transcription kit (Applied Biosystems).
qPCR was performed in 384-well plates in triplicates using SYBR
green I master mix (Roche) in a Roche LightCycler 480. Relative
mRNA values were calculated using the DDCt method using 18S
rRNA as internal control and plotted as fold change by
normalizing to mock-control samples.
UBR4 qPCR primers: Forward =GGTGTTCCAGAGGC-
TAGTGATC; Reverse =CCAACTGCTTCTGCGGTTCCTT
ISG15 qPCR primers: Forward=TCCTGGTGAGGAATAA-
CAAGGG; Reverse =GTCAGCCAGAACAGGTCGTC
RIG-I qPCR primers: Forward =GGCATGTTACACAGCT-
GACG; Reverse =TGCAATATCCTCCACCACAA
ISG54 qPCR primers: Forward=ATGTGCAACCTACT-
GGCCTAT; Reverse =TGAGAGTCGGCCCATGTGATA
18S RNA qPCR primers: Forward =GTAACCCGTTGAA-
CCCCATT; Reverse =CCATCCAATCGGTAGTAGCG
Flow cytometry
DENV-infected DCs were fixed and permeabilized with Cytofix
and Cytoperm reagent (BD Pharmingen) according to the
manufacturer’s recommendations. Then, cells were stained with
4G2 (ATCC), a mouse monoclonal antibody specific for the E
protein, as a primary antibody and a FITC-labeled anti-mouse
antibody as a secondary antibody. Flow cytometry was performed
using a FACScan flow cytometer (Becton Dickinson) and analyzed
with FlowJo software.
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